Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, open-label study in stable patients switched from typical and atypical oral antipsychotics

被引：0
|
作者：
Cetin, M [1 ]
Ebrinc, S [1 ]
Basoglu, C [1 ]
Semiz, UB [1 ]
Gunay, H [1 ]
Iyisoy, MS [1 ]
Ergun, BM [1 ]
Gunes, C [1 ]
Sahan, A [1 ]
Oguz, M [1 ]
Noyan, O [1 ]
机构：
[1] Gulhane Haydarpasa Training Hosp, Dept Psychiat, Istanbul, Turkey
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
10.1016/S0924-977X(05)80287-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S134 / S135
页数：2
相关论文
共 50 条
  • [41] Walking intervention and dietary guidance efficacy for overweight people with schizophrenia: An open-label 12-week study
    Kishi, Taro
    Okuya, Makoto
    Sakuma, Kenji
    Otaka, Yohei
    Saitoh, Eiichi
    Iwata, Nakao
    PSYCHIATRY AND CLINICAL NEUROSCIENCES REPORTS, 2022, 1 (04):
  • [42] Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial
    Lublin, Henrik
    Haug, Hans-Joachim
    Koponen, Hannu
    Sigmundsson, Thordur
    Kolb, Stefan A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04): : 710 - 718
  • [43] INSIGHT AND ITS RELATIONSHIP TO BASELINE CHARACTERISTICS OF SCHIZOPHRENIA PATIENTS RANDOMIZED TO LONG-ACTING INJECTABLE RISPERIDONE OR ORAL ATYPICAL ANTIPSYCHOTICS: RESULTS FROM THE PROACTIVE STUDY
    Koola, Maju Mathew
    Bustillo, J.
    Lauriello, J.
    SCHIZOPHRENIA BULLETIN, 2009, 35 : 360 - 361
  • [44] Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
    Lasser, RA
    Bossie, CA
    Zhu, Y
    Gharabawi, G
    Eerdekens, M
    Davidson, M
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (09) : 898 - 905
  • [45] Efficacy and safety of long-acting risperidone on early onset schizophrenia in adolescent patients
    Ruan, Liming
    Hu, Shaohua
    Huang, Manli
    Hu, Jianpo
    Cai, Wei
    AFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 4 (05): : 184 - 192
  • [46] The Efficacy and Safety of Lacosamide for Bipolar Depression A 12-Week Open-Label Pilot Trial
    Kishi, Taro
    Nomura, Ikuo
    Sakuma, Kenji
    Okuya, Makoto
    Oya, Kazuto
    Iwata, Nakao
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (02) : 204 - 206
  • [47] Switching therapy from conventional and atypical antipsychotics to ziprasidone in outpatients with schizophrenia: an 8 week, open-label study
    Rossi, A.
    Vita, A.
    Sciarretta, A.
    Romeo, F.
    Tiradritti, P.
    Rappard, F.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 457 - 458
  • [48] A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients
    Takekita, Yoshiteru
    Kato, Masaki
    Wakeno, Masataka
    Sakai, Shiho
    Suwa, Azusa
    Nishida, Keiichiro
    Okugawa, Gaku
    Kinoshita, Toshihiko
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 40 : 110 - 114
  • [49] Risperidone long-acting injectable improves efficacy and safety in schizophrenic patients after changing from oral risperidone
    Kusters, J
    Glue, P
    Katsafouros, K
    Boon, H
    Medori, R
    Parellada, E
    EUROPEAN PSYCHIATRY, 2005, 20 : S79 - S79
  • [50] Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients
    Girardi, P.
    Serafini, G.
    Pompili, M.
    Innamorati, M.
    Tatarelli, R.
    Baldessarini, R. J.
    PHARMACOPSYCHIATRY, 2010, 43 (02) : 66 - 72
12345